ORCHARD THERAPEUTICS NORTH AMERICA

Lobbying for ORCHARD THERAPEUTICS NORTH AMERICA · Health

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Expenses

$240,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Massachusetts

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including Appropriations and Accelerating Implementation and Providing Resources for States to Implement for Metachromatic Leukodystrophy (MLD) H.R. 10571: Surge to Save Newborns Act

Medicare/Medicaid

S.1637/H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act CMS Policies to Support Expedited Implementation of Accelerating Kids' Access to Care Act (AKATCA) and States' Awareness of VBAs

Bills named in this filing 3

H.R. 10571
Surge to Save Newborns Act
S. 1637
MVP Act
H.R. 7871
MVP Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.